Effect of Hejie decoction on T cell immune state of chronic hepatitis B patients

doi:10.3748/wjg.v10.i10.1436

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 10

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2889)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

228

HTML

2473

Tables (1-3)

188

Sum=2889

May 15, 2004 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. May 15, 2004; 10(10): 1436-1439
Published online May 15, 2004. doi: 10.3748/wjg.v10.i10.1436

Table 1 ALT, AST, TB and HBVDNA levels before and after treatment (mean ± SD)

		n	ALT (U/L)	AST (U/L)	TB (μmol/L)	HBVDNA (copy/mL)
Normal		10	27.80 ± 8.65	19.07 ± 8.50	12.55 ± 5.52	0
Treatment	Pre-T	40	213.66 ± 10.30	134.66 ± 9.82	41.03 ± 4.36	(1.52 ± 0.72) × 10^8.25
	Post-T	40	37.01 ± 9.75^b	29.07 ± 8.97^b	20.55 ± 5.52^b	(4.25 ± 1.90) × 10^{6.02 a}
Control	Pre-T	25	195.70 ± 11.11	125.12 ± 9.21	40.87 ± 6.78	(1.32 ± 0.89) × 10^8.12
	Post-T	25	36.01 ± 9.75^b	69.88 ± 8.97^b	30.55 ± 5.52^b	(6.95 ± 2.39) × 10^7.82

n: Number; normal: Normal group; treatment: Treatment group; control: Control group; Pre-T: Before treatment; Post-T: After treatment; ^aP < 0.05, vs before treatment in the same group, ^bP < 0.01, vs before treatment in the same group.

Table 2 T lymphocyte subsets before and after treatment (mean ± SD)

		n	CD₃ (%)	CD₄ (%)	CD₈ (%)	CD₄/CD₈
Normal		10	67.80 ± 8.65	39.07 ± 8.50	30.55 ± 5.52	1.62 ± 0.46
Treatment	Pre-T	40	65.97 ± 8.45	34.76 ± 4.82^b	34.08 ± 4.36^b	1.04 ± 0.32
	Post-T	40	67.01 ± 9.75	37.39 ± 8.97^a	32.35 ± 5.52^a	1.20 ± 0.30^a
Control	Pre-T	25	65.70 ± 9.11	35.02 ± 5.21^b	34.87 ± 6.78^b	1.02 ± 0.29
	Post-T	25	66.01 ± 9.75	35.88 ± 8.97	34.15 ± 5.52	1.09 ± 0.39

n: Number; normal: Normal group; treatment: Treatment group; control: Control group; Pre-T: Before treatment; Post-T: After treatment;

^aP < 0.05, vs before treatment in the same group,

^bP < 0.01, vs control.

Table 3 T lymphocyte subsets of responders and non-respond-ers in treatment group before and after treatment (mean ± SD)

		n	CD₃ (%)	CD₄ (%)	CD₈ (%)
Responders	Pre-T	6	66.62 ± 8.86	35.10 ± 4.76^b	34.02 ± 4.86^b
	Post-T	6	66.80 ± 9.11	38.85 ± 8.85^a	30.15 ± 5.82^a
Non-responders	Pre-T	34	65.86 ± 9.08	34.62 ± 6.30^b	34.17 ± 6.56^b
	Post-T	34	66.09 ± 9.35	35.72 ± 8.70	33.85 ± 5.52
Normal		10	67.80 ± 8.65	39.07 ± 8.50	30.55 ± 5.52

n: Number; responders: Patients who had normal ALT and HBeAg and HBV DNA after treatment; non-responders: Pa-tients who had abnormal ALT, HBeAg and HBV DNA after treatment; normal: Normal group; Pre-T: Before treatment; Post-T: After treatment;

^aP < 0.05, vs before treatment in the same group,

^bP < 0.01, vs normal group.

Citation: Zhang SJ, Chen ZX, Lao SX, Huang BJ. Effect of Hejie decoction on T cell immune state of chronic hepatitis B patients. World J Gastroenterol 2004; 10(10): 1436-1439
URL: https://www.wjgnet.com/1007-9327/full/v10/i10/1436.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i10.1436